Perawatan Akut Anyar kanggo Migrain

Theranica, terapi digital sing diresepake developing advanced electroceuticals for migraine and other pain conditions, announced today the publication of a new peer-reviewed study analyzing the efficacy, safety and of remote electrical neuromodulation (REN) as a standalone, and medication adjunct, treatment of migraine. The real-world evidence study published in Frontiers in Pain Research Journal concludes that REN, administered by Theranica’s flagship product Nerivio®, performs well across all three parameters.

Asil saka analisis luwih saka 23,000 perawatan, sing diklumpukake sajrone 19 wulan, nuduhake khasiat REN sing signifikan. Ing 66.5% perawatan, REN digunakake minangka perawatan mandiri. Kira-kira 80% saka perawatan, ora ana obat resep liyane sing digunakake. Saka 2,514 pasien kalebu ing analisis khasiat, 32% saka pasien migrain episodik lan 21% saka pasien migren kronis, entuk kebebasan nyeri rong jam sawise perawatan ing sebagian besar perawatan, lan luwih saka 65% ngalami nyeri sing terus-terusan sawise rong jam. . Ing analisis safety, mung 59 saka 12,368 peserta (0.48%) nglaporake kedadeyan ala sing gegandhengan karo piranti, sing paling akeh entheng (56) tanpa ana laporan kedadeyan sing abot.

Dipakani ing lengen ndhuwur nalika serangan migren, Nerivio nyuda nyeri sirah migren lan gejala sing gegandhengan kanthi nggunakake REN kanggo micu mekanisme analgesik endogen, sing dikenal minangka modulasi nyeri berkondisi (CPM). Piranti kasebut dikontrol liwat aplikasi smartphone, ngidini pasien nyetel intensitas perawatan lan uga njaga buku harian migren sing dibangun kanthi gampang bisa dituduhake karo dokter kanggo nelusuri lan manajemen migren sing luwih apik.

Nerivio minangka piranti sing bisa disambungake kanthi digital. Pasinaon klinis wis nuduhake yen Nerivio efektif lan aman kanggo perawatan migren episodik lan kronis ing individu sing umure 12 lan luwih.

Print Friendly, PDF & Email

Berita sing gegandhengan